WAVE Life Sciences (NASDAQ: WVE) has filed the following prospectus:

This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 4, 2022 (the “Prospectus”), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $131,974,010 (the “Maximum Offering Amount”) of our ordinary shares, no par value (“Ordinary Shares”), that may be issued and sold under a sales agreement with Jefferies LLC (the “ATM Facility”).

Effective as of September 24, 2024, we have reduced the Maximum Offering Amount to $0 and no longer intend to sell our Ordinary Shares under the Prospectus unless we file a further prospectus supplement indicating an amount of shares proposed to be sold. As of the date of this prospectus supplement, 3,314,382 Ordinary Shares have been sold under the ATM Facility pursuant to the Prospectus, for aggregate gross proceeds of approximately $19.0 million, before deducting sales agent’s commissions.